2026-03-06T02:13:44Z https://repository.lib.tottori-u.ac.jp/oai

oai:repository.lib.tottori-u.ac.jp:00007104 2023-11-22T01:45:39Z 1:9 2:12

Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer 小山, 哲史 4942 コヤマ, サトシ 100002206 Koyama, Satoshi 藤原, 和典 369 フジワラ, カズノリ 90403419 Fujiwara, Kazunori 100000417 三宅, 成智 2191 ミヤケ, ナリトモ 60464278 Miyake, Naritomo 100001499 福原, 隆宏 405 フクハラ, タカヒロ 80403418 Fukuhara, Takahiro 100001318 竹内, 裕美 3674 タケウチ, ヒロミ 40197273 Takeuchi, Hiromi 100000179 Morisaki, Tsuyoshi 26282 Recurrent and metastatic Head and neck cancer Second-line Successive Chemotherapy Recurrent and metastatic Head and neck cancer Second-line Successive Chemotherapy ObjectiveThe increase in treatment options resulted in successful treatment with multiple lines of chemotherapy for recurrent and metastatic (RM) head and neck cancer (HNC). The present study aimed to elucidate the beneficial effect of successive treatment for RM-HNC. MethodsWe included 78 patients with RM-HNC who received one or multiple lines of chemotherapy from January 2008 to December 2019. We divided the patients into three groups according to treatment period: January 2008 to November 2012 included those who underwent cancer chemotherapy only with cytotoxic agents (Tox group), December 2012 to March 2017 included those who received cytotoxic agents and cetuximab (Cet group), and March 2017 to December 2019 included those who received cytotoxic agents, cetuximab and immune checkpoint inhibitor nivolumab (Nivo group). Moreover, we compared the overall survival of the three groups. ResultsIn total, 18, 33, and 27 patients were included in the Tox, Cet, and Nivo groups, respectively. The median overall survival were 8.5 months in the Tox group, 16 months in the Cet group, and 19 months in the Nivo group, and the difference in the result was significant. ConclusionsSuccessive treatment with second and subsequent lines of chemotherapy in patients with RM-HNC improves prognosis. journal article Elsevier B.V. 2021-02 AM application/pdf Auris Nasus Larynx 1 48 161 165 Auris Nasus Larynx 03858146 https://repository.lib.tottori-u.ac.jp/record/7104/files/anl48(1)_161.pdf https://repository.lib.tottori-u.ac.jp/records/7104 eng 10.1016/j.anl.2020.07.016 Koyama, Satoshi. Fujiwara, Kazunori. Morisaki, Tsuyoshi. et al. Efficacy of second and subsequent lines of chemotherapy for recurrent and metastatic head and neck cancer. Auris Nasus Larynx. 2021. 48(1), 161-165. https://www.sciencedirect.com/science/article/pii/S0385814620301978 https://www.sciencedirect.com/science/article/pii/S0385814620301978 © 2020 Oto-Rhino-Laryngological Society of Japan Inc. Published by Elsevier B.V. All rights reserved.